Get the Stockscreener App
2.38
6.37%
+0.1426
After Hours:
2.41
0.03
+1.26%
Can-Fite Biopharma Ltd ADR Stock (CANF) Forecast
The Can-Fite Biopharma Ltd ADR (CANF) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $30.45, representing a +1,179% increase from the current price of $2.38. The highest analyst price target is $29.15, and the lowest is $31.75.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month CANF Price Target
Average 30.85
(+1,196% Upside)
Is Can-Fite Biopharma Ltd ADR (CANF) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 65.31 | Neutral |
| STOCH(9,6) | 48.19 | Neutral |
| STOCHRSI(14) | 100.00 | Sell |
| MACD(12,26) | 0.0281 | Buy |
| ADX(14) | 31.70 | Buy |
| William %R | -11.63 | Sell |
| CCI(14) | 312.38 | Buy |
Buy: 3
Sell: 2
Neutral: 2
Summary: Buy
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
2.1364
Buy
|
2.1602
Buy
|
| MA20 |
2.0702
Buy
|
2.1235
Buy
|
| MA50 |
2.147
Buy
|
2.1196
Buy
|
| MA100 |
2.1042
Buy
|
2.1467
Buy
|
| MA200 |
2.2429
Buy
|
2.2827
Buy
|
Buy: 10
Sell: 0
Neutral: 0
Summary: Buy
According to our latest analysis, CANF could be considered a Strong Buy, with 17 technical analysis indicators signaling 13 Buy signals, 2 signaling Sell signals and 2 Neutral signals. This might be a good time to open fresh positions on CANF, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 65.31 indicates that CANF is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 48.19 indicates that CANF is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 100 indicates that CANF is oversold. This suggests that CANF price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 31.7 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 312.38 indicates that CANF is overbought. This means that the price has moved significantly higher than its average, indicating a potential selling opportunity.
Long-term CANF price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Can-Fite Biopharma Ltd ADR financial reports and earnings history, Can-Fite Biopharma Ltd ADR (CANF) stock could reach $89.00 by 2030, $42.53 by 2040 and $128.59 by 2050. See the projected annual prices until 2050 of the Can-Fite Biopharma Ltd ADR stock below:
- Can-Fite Biopharma Ltd ADR (CANF) is expected to reach an average price of $13.21 in 2035, with a high prediction of $14.81 and a low estimate of $13.42. This indicates an $454.91% rise from the last recorded price of $2.38.
- Can-Fite Biopharma Ltd ADR (CANF) stock is projected to chart a bullish course in 2040, with an average price target of $41.54, representing an $1,645% surge from its current level. The forecast ranges from a conservative $41.60 to a sky-high $42.53.
- Our analysts predict Can-Fite Biopharma Ltd ADR (CANF) to jump 3,106% by 2045, soaring from $77.11 to an average price of $76.29, potentially reaching $77.02. While $77.11 is the low estimate, the potential upside is significant.
- Can-Fite Biopharma Ltd ADR (CANF) stock is expected to climb by 2050, reaching an average of $127.77, a $5,268% jump from its current level. However, a wide range of estimates exists, with high and low targets of $128.59 and $129.16, respectively, highlighting the market's uncertainty.
Can-Fite Biopharma Ltd ADR Stock (CANF) Year by Year Forecast
Can-Fite Biopharma Ltd ADR Stock (CANF) Price Forecast for 2024
Our forecast for CANF stock price in 2024 now indicates an average price target of $18.71 with a high forecast of $35.55 and a low forecast of $1.87. The average prediction reflects an increase of +686.09% from the last recorded price of $2.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| June, 2024 | $29.85 | $31.75 | $29.15 | +1,154% |
| July, 2024 | $29.45 | $29.15 | $27.35 | +1,137% |
| August, 2024 | $35.05 | $31.46 | $31.25 | +1,373% |
| September, 2024 | $33.46 | $33.85 | $33.15 | +1,306% |
| October, 2024 | $29.75 | $35.35 | $35.55 | +1,150% |
| November, 2024 | $31.60 | $33.15 | $31.28 | +1,228% |
| December, 2024 | $17.55 | $22.65 | $29.45 | +637.34% |
Can-Fite Biopharma Ltd ADR Stock (CANF) Price Forecast for 2025
Can-Fite Biopharma Ltd ADR Stock (CANF) is expected to reach an average price of $30.85 in 2025, with a high prediction of $39.36 and a low estimate of $22.35. This indicates an +1,196% rise from the last recorded price of $2.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $19.45 | $22.35 | $20.95 | +717.07% |
| February, 2025 | $31.05 | $26.05 | $27.75 | +1,204% |
| March, 2025 | $39.05 | $33.25 | $39.36 | +1,541% |
| April, 2025 | $37.65 | $38.19 | $36.94 | +1,482% |
| May, 2025 | $31.64 | $31.84 | $33.84 | +1,230% |
| June, 2025 | $30.64 | $31.94 | $30.95 | +1,188% |
| July, 2025 | $30.24 | $29.54 | $29.75 | +1,171% |
| August, 2025 | $29.04 | $28.34 | $28.46 | +1,120% |
| September, 2025 | $24.74 | $23.44 | $24.14 | +939.61% |
| October, 2025 | $29.34 | $23.64 | $22.97 | +1,133% |
| November, 2025 | $26.94 | $27.34 | $26.64 | +1,032% |
| December, 2025 | $26.34 | $26.34 | $26.54 | +1,007% |
Can-Fite Biopharma Ltd ADR Stock (CANF) Price Forecast for 2026
The predicted value for Can-Fite Biopharma Ltd ADR (CANF) in 2026 is set at an average of $19.29. Estimates vary from a peak of $25.14 to a trough of $13.44, indicating an +710.48% surge from the present price of $2.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $24.04 | $25.14 | $25.14 | +910.13% |
| February, 2026 | $23.64 | $23.84 | $23.04 | +893.30% |
| March, 2026 | $22.24 | $23.04 | $22.94 | +834.46% |
| April, 2026 | $16.74 | $17.44 | $20.74 | +603.35% |
| May, 2026 | $11.24 | $19.84 | $19.24 | +372.24% |
| June, 2026 | $14.84 | $14.84 | $14.24 | +523.48% |
| July, 2026 | $16.84 | $16.84 | $16.64 | +607.50% |
| August, 2026 | $14.34 | $16.14 | $15.14 | +502.44% |
| September, 2026 | $12.64 | $13.74 | $13.14 | +430.99% |
| October, 2026 | $13.84 | $13.44 | $13.69 | +481.39% |
| November, 2026 | $15.64 | $16.14 | $15.14 | +557.00% |
| December, 2026 | $16.64 | $16.39 | $16.04 | +599.00% |
Can-Fite Biopharma Ltd ADR Stock (CANF) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Can-Fite Biopharma Ltd ADR (CANF) is $16.78, with a high forecast of $19.04 and a low forecast of $14.53. This indicates an +605.13% increase from the last price of $2.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $17.04 | $16.94 | $16.44 | +615.79% |
| February, 2027 | $19.54 | $17.44 | $16.84 | +720.82% |
| March, 2027 | $17.93 | $19.84 | $19.04 | +653.57% |
| April, 2027 | $16.73 | $17.23 | $15.93 | +603.13% |
| May, 2027 | $17.73 | $17.63 | $17.53 | +645.13% |
| June, 2027 | $16.83 | $16.93 | $17.01 | +607.29% |
| July, 2027 | $14.83 | $16.03 | $16.83 | +523.24% |
| August, 2027 | $16.73 | $15.13 | $14.93 | +603.06% |
| September, 2027 | $16.44 | $16.93 | $16.61 | +590.56% |
| October, 2027 | $16.03 | $16.03 | $15.43 | +573.48% |
| November, 2027 | $14.83 | $15.43 | $14.83 | +523.17% |
| December, 2027 | $13.93 | $14.53 | $14.74 | +485.34% |
Can-Fite Biopharma Ltd ADR Stock (CANF) Price Forecast for 2028
In 2028, Can-Fite Biopharma Ltd ADR (CANF) is projected to reach an average price of $11.49, with a high projection of $13.49 and a low estimate of $9.4958. This indicates an +382.85% rise from the last price of $2.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $13.29 | $13.43 | $13.49 | +458.43% |
| February, 2028 | $13.53 | $13.13 | $13.33 | +468.54% |
| March, 2028 | $11.51 | $11.82 | $13.13 | +383.52% |
| April, 2028 | $10.71 | $11.43 | $11.12 | +349.93% |
| May, 2028 | $12.03 | $10.83 | $11.23 | +405.37% |
| June, 2028 | $12.80 | $12.40 | $11.71 | +437.75% |
| July, 2028 | $13.39 | $13.13 | $12.90 | +462.52% |
| August, 2028 | $13.35 | $13.38 | $13.32 | +460.82% |
| September, 2028 | $12.85 | $12.98 | $12.90 | +439.79% |
| October, 2028 | $12.12 | $12.52 | $12.76 | +409.11% |
| November, 2028 | $10.44 | $10.77 | $11.88 | +338.50% |
| December, 2028 | $9.3558 | $9.4958 | $10.06 | +293.10% |
Can-Fite Biopharma Ltd ADR Stock (CANF) Price Forecast for 2029
The 2029 price forecast for Can-Fite Biopharma Ltd ADR Stock (CANF) is $27.81 on average, with a high prediction of $55.40 and a low estimate of $0.2206. This represents an +1,068% increase from the previous price of $2.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $8.4053 | $8.4615 | $9.0057 | +253.16% |
| February, 2029 | $7.8749 | $8.1069 | $8.1352 | +230.88% |
| March, 2029 | $7.1645 | $7.2244 | $7.4749 | +201.03% |
| April, 2029 | $6.7441 | $6.8442 | $6.9144 | +183.37% |
| May, 2029 | $6.0836 | $6.1022 | $6.6013 | +155.61% |
| June, 2029 | $4.7832 | $4.9132 | $5.7335 | +100.97% |
| July, 2029 | $4.2228 | $4.3328 | $4.653 | +77.43% |
| August, 2029 | $3.3123 | $3.4823 | $3.9732 | +39.17% |
| September, 2029 | $2.5619 | $2.6219 | $3.0831 | +7.64% |
| October, 2029 | $1.3914 | $1.5835 | $2.2718 | -41.54% |
| November, 2029 | $0.841 | $0.881 | $1.1213 | -64.66% |
| December, 2029 | $58.76 | $0.2206 | $55.40 | +2,369% |
Can-Fite Biopharma Ltd ADR Stock (CANF) Price Forecast for 2030
Can-Fite Biopharma Ltd ADR Stock (CANF) is expected to reach an average price of $81.60 in 2030, with a high forecast of $92.00 and a low forecast of $71.20. This signifies an +3,328% surge from the last price of $2.38.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $91.20 | $71.20 | $89.00 | +3,732% |
| February, 2030 | $87.54 | $89.30 | $88.30 | +3,578% |
| March, 2030 | $88.80 | $88.00 | $85.80 | +3,631% |
| April, 2030 | $90.50 | $91.36 | $88.90 | +3,702% |
| May, 2030 | $92.20 | $90.90 | $92.00 | +3,774% |
| June, 2030 | $90.49 | $90.84 | $91.00 | +3,702% |
| July, 2030 | $82.59 | $86.19 | $86.53 | +3,370% |
| August, 2030 | $79.49 | $76.39 | $74.79 | +3,240% |
| September, 2030 | $78.89 | $76.09 | $73.53 | +3,215% |
| October, 2030 | $91.94 | $78.69 | $91.40 | +3,763% |
| November, 2030 | $88.26 | $89.99 | $88.24 | +3,608% |
| December, 2030 | $85.39 | $88.39 | $87.59 | +3,488% |
0.77%
1.20%
Cap:
|
Volume (24h):